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General experimental: 
FTIR spectra were recorded on Perkin-Elmer-FT-IR 1725X spectrophotometer; values 
are given in cm-1. 1H and 13C NMR spectra were recorded on a Varian Gemini 200 and Bruker 
Avance III 500 spectrometers at 200/50 and 500/125 MHz, respectively. The chemical shifts 
were measured to residual nondeuterated solvent resonances or TMS. Fullerenic carbons, 
presented as Cf, were numbered in a simplified way, according to the literature.1 Mass spectra 
were obtained on Agilent technologies 6210 TOF LC/MS instrument. UV spectra were recorded 
on a GBC-Cintra 40 spectrophotometer. Reactions were monitored by TLC using plates 
precoated with silica gel 60 F254. Column chromatography was performed on Silica, 10-18, 
60A, ICN Biomedicals. Standard techniques were used for the purification of reagent and 
solvents.2 Reactions induced by microwave irradiation were performed in a Milestone 
MultiSynth microwave multimode oven, using a MedCHEM kit and MonoPREP kit.  
Investigations of samples morphology were carried out with scanning electron 
microscopy, using a JEOL JSM-840A instrument, at an acceleration voltage of 30 kV. A several 
drops of a dilute solution (~1 mM in toluene, dioxane, methanol, toluene/dioxane (2:1), 
toluene/iso-propanol (1:1 and 2:1), and chloroform/methanol (2:1)) of fullero-phthalimide dyads 
were deposited on the surface of Si wafer and then slowly evaporated in a glass petri dish 
(diameter 10 cm) under toluene atmosphere at the room temperature. The investigated samples 
were gold sputtered in a JFC 1100 ion sputterer and then subjected to SEM observations. 
 
Preparation of mono-protected diamines 2a-f  
To a stirred solution of diamine (0.06 mol) in chloroform (150 mL), di-tert-butyl dicarbonate 
(0.01 mol) dissolved in chloroform (50 mL) was added via dropping funnel over 1 hour at room 
temperature. The reaction mixture was stirred overnight and the solvent was removed under 
reduced pressure. Pure amides 2a-f were obtained as oils in 37-66% yields by SiO2 column 
chromatography using EtOAc-toluene mixtures. 
Tert-butyl 2-aminoethylcarbamate (2a): 1.9 g (66%); All obtained spectra were in accordance 
with reported procedure.3 
Tert-butyl 4-aminobutylcarbamate (2b): 1.1 g (43%); IR (ATR): 3365, 2934, 2858, 1686, 
1526, 1280, 1251, 1173, 780 cm-1; 1H NMR (CDCl3, 200 MHz):  = 5.09 (bs, 1H); 3.13 (m, 2H); 
2.71 (t, 2H, J=6.2); 1.60-1.44 (m, 13H); 13C NMR (CDCl3, 50 MHz):  = 155.9 (C); 78.6 (C); 
41.4 (CH2); 40.1 (CH2); 33.4 (CH2); 28.1 (3CH3); 27.2 (CH2); HRMS: m/z calcd for 
[C9H20N2O2+H]+ 189.1597, measured 189.1597; All obtained spectra were in accordance with 
reported procedure.3 
Tert-butyl 6-aminohexylcarbamate (2c): 1.1g (42%); IR (ATR): 3344, 2934, 2868, 1690, 
1525, 1276, 1254, 1172, 751 cm-1; 1H NMR (CDCl3, 200 MHz):  = 4.90 (s, 1H); 3.11-3.07 (m, 
2H); 2.69 (t, 2H,  J=7); 1.56-1.33 (m, 17H); 13C NMR (CDCl3, 50 MHz):  = 155.9 (C); 78.7
(C); 41.3 (CH2); 40.2 (CH2); 32.4 (CH2); 29.8 (CH2); 28.2 (3CH3); 26.3 (CH2); 26.2 (CH2); 
HRMS: m/z calcd for [C11H24N2O2+H]+ 217.1910, measured 217.1912; All obtained spectra 
were in accordance with reported procedure.3 
Tert-butyl 8-aminooctylcarbamate (2d): 1.3 g (58%); IR (ATR): 3367, 2924, 2853, 1688, 
1523, 1249, 1172, 807 cm-1; 1H NMR (CDCl3, 200 MHz):  4.51 (bs, 1H); 3.09 (q, 2H, J=6.2); 
2.68 (t, 2H, J=4.6); 1.51-1.36 (m, 6H); 1.44 (s, 9H); 1.36-1.20 (m, 6H); 13C NMR (CDCl3, 50 
MHz):  = 156.0 (C); 79.1 (C); 42.1 (CH2); 40.6 (CH2); 33.6 (CH2); 29.9 (CH2); 29.3 (CH2); 
29.2 (CH2); 28.4 (3CH3); 26.7 (CH2); 26.6 (CH2); HRMS: m/z calcd for [C13H28N2O2+H]+ 
245.2223, measured 245.2224; All obtained spectra were in accordance with reported 
procedure.3 
Tert-butyl 10-aminodecylcarbamate (2e): 1.2 g (37%); IR (ATR): 3367, 2924, 2854, 1690, 
1524, 1283, 1249, 1175, 782 cm-1; 1H NMR (CDCl3, 200 MHz):  = 4.65 (bs, 1H); 3.09 (q, 2H, 
J=6.2); 2.7 (t, 2H, J=6.8); 1.55-1.44 (m, 13H); 1.32-1.12 (m, 12H); 13C NMR (CDCl3, 50 MHz): 
 = 155.9 (C); 78.8 (C); 41.7 (CH2); 40.5 (CH2); 29.9 (CH2); 29.4 (2CH2); 29.3 (CH2); 29.2 
(CH2); 29.1 (CH2); 28.3 (3CH3); 26.7 (CH2); 26.6 (CH2); HRMS: m/z calcd for 
[C15H32N2O2+H]+ 273.2536, measured 273.2546; All obtained spectra were in accordance with 
reported procedure.3 
Tert-butyl 12-aminododecylcarbamate (2f): 2.0 g (55%); IR (ATR): 3362, 2922, 2853, 1689, 
1524, 1281, 1248, 1173.0, 722.3 cm-1;  1H NMR (CDCl3, 200 MHz):  = 4.64 (bs, 1H); 3.10 (q, 
2H, J=6.2); 2.68 (t, 2H, J=6.6); 1.55-1.38 (m, 12H); 1.33-1.23 (m, 17H); 13C NMR (CDCl3, 50 
MHz):  = 155.9 (C); 78.8 (C); 42.1 (CH2); 40.5 (CH2); 33.6 (CH2); 29.9 (2CH2); 29.4 (2CH2); 
29.3 (2CH2); 29.1 (CH2); 28.3 (3CH3); 26.8 (CH2); 26.7 (CH2); HRMS: m/z calcd for 
[C17H36N2O2+H]+ 301.2849, measured 301.2863; All obtained spectra were in accordance with 
reported procedure.3 
Preparation of benzyloxy-derivates (3a-f) 
To a stirred, ice bath cooled solution of amine 2a-f (2 mmol) and Et3N (6 mmol, 0.44 mL) in dry 
CH2Cl2 (8 mL) a solution of benzyl bromoacetate (1.6 mmol, 1.1 mL) in dry CH2Cl2 (2 mL) was 
added dropwise over 1 hour. The reaction mixture was stirred at room temperature for an 
additional 30 h. The resulting mixture was diluted with water, organic phase washed with H2O (2 
x 10 mL), brine (2 x 10 mL) and dried over anh. Mg2SO4. The solvent was evaporated and the 
remaining crude product was chromatographed on a SiO2 column. Elution with EtOAc-toluene 
(6/4) mixture gave the products 3a-f as yellow oils in 39-62% yields. 
Benzyl 2-(2-(tert-butoxycarbonylamino)ethylamino)acetate (3a): 271.0 mg (55%); The 
obtained spectra were in accordance with reported procedure.4 
Benzyl 2-(4-(tert-butoxycarbonylamino)butylamino)acetate (3b): 229.9 mg (41%); IR 
(ATR): 3338, 2933, 1740, 1704, 1521, 1174, 748 cm-1; 1H NMR (CDCl3, 200 MHz):  = 7.36 (s, 
5H); 5.16 (s, 2H); 4.70 (bs, 1H); 3.44 (s, 2H); 3.12-3.09 (m, 2H); 2.64-2.58 (m, 2H); 1.56-1.47 
(m, 13H);  13C NMR (CDCl3, 50 MHz):  = 172.4 (C); 155.9 (C); 135.5 (C); 128.6 (2CH); 128,3 
(3CH); 78.6 (C); 66.5 (CH2); 50.8 (CH2); 49.0 (CH2); 40.3 (CH2); 28.3 (3CH3); 27.6 (CH2); 27.2 
(CH2); HRMS: m/z calcd for [C18H28N2O4+H]+ 337.2122, measured 337.2131; The obtained 
spectra were in accordance with reported procedure.5 
Benzyl 2-(6-(tert-butoxycarbonylamino)hexylamino)acetate (3c): 235.9 mg (39%); IR 
(ATR): 3343, 2931, 2859,1740, 1707, 1523, 1173, 755 cm-1; 1H NMR (CDCl3, 200 MHz):  = 
7.34 (s, 5H); 5.15 (s, 2H), 4.85 (bs, 1H); 3.43 (s, 2H); 3.09-3.06 (m, 2H); 2.58 (t, 2H , J=6.8); 
1.54-1.34 (m, 17H);  13C NMR (CDCl3, 50 MHz):  = 171.9 (C,); 155.5 (C); 135.1 (C); 128.1 
(2CH); 127.9 (3CH); 78.3 (C); 65.9 (CH2); 50.4 (CH2); 48.9 (CH2); 39.9 (CH2); 29.4 (CH2); 27.9 
(3CH3); 26.3 (CH2); 26.1 (CH2); HRMS: m/z calcd for [C20H32N2O4+H]+ 365.2435, measured 
365.2445; The obtained spectra were in accordance with reported procedure.6 
Benzyl 2-(8-(tert-butoxycarbonylamino)octylamino)acetate (3e): 364.0 mg (58%); IR (ATR): 
3357, 2930, 2859, 1741, 1689, 1172, 737 cm-1; 1H NMR (CDCl3, 200 MHz):  = 7.36 (s, 5H); 
5.17 (s, 2H); 3.45 (s, 2H); 3.14-3.04 (m, 2H); 2.59 (t, 2H , J=7); 1.56-1.26 (m, 22H);  13C NMR 
(CDCl3, 50 MHz):  = 172.5 (C); 155.9 (C); 135.6 (C); 128.6 (2CH); 128.3 (3CH); 78.9 (C); 
66.4 (CH2); 50.9 (CH2); 49.5 (CH2); 40.5 (CH2); 30.0 (CH2); 29.3 (CH2); 29.1 (CH2); 28.3 
(3CH3); 27.0 (CH2); 26.6 (CH2); HRMS: m/z calcd for [C22H36N2O4+H]+ 393.2748, measured 
393.2753;  
Benzyl 2-(10-(tert-butoxycarbonylamino)decylamino)acetate (3e): 286.2 mg (48%); IR 
(ATR): 3340, 2927, 2854, 1712, 1518, 1174, 735; 1H NMR (CDCl3, 200 MHz):  = 7.36 (s, 5H); 
5.17 (s, 2H); 4.52 (bs, 1H); 3.46 (s, 2H); 3.09 (q, 2H, J=6.2); 2.59 (t, 2H , J=6.6); 1.60-1.44 (m, 
13H); 1.33-1.15 (m, 12H);  13C NMR (CDCl3, 50 MHz):  = 172.5 (C); 168.7(C); 135.6 (C); 
128.6 (2CH); 128,4 (3CH); 78.3 (C); 66,5 (CH2); 50.9 (CH2); 49.6 (CH2); 40.6 (CH2); 30.0 
(CH2); 29.4 (2CH2); 29.2 (2CH2);  28.4 (3CH3); 27.1 (CH2); 26.7 (CH2); HRMS:  m/z calcd for 
[C24H40N2O4+H]+ 421.3061, measured 421.3043; 
Benzyl 2-(12-(tert-butoxycarbonylamino)dodecylamino)acetate (3f): 445.0 mg, (62%); IR 
(ATR): 3353, 2923,  2855, 1731, 1521, 1177, 745 cm-1;  1H NMR (CDCl3, 200 MHz):  = 7.36 
(s, 5H); 5.17 (s, 2H); 4.53 (bs, 1H); 3.45 ( s, 2H); 3.09 (q, 2H, J=6.2); 2.59 (t, 2H , J=7.2); 1.60-
1.44 (m, 13H); 1.33-1.14 (m, 16H);  13C NMR (CDCl3, 50 MHz):  = 172.5 (C); 160.0(C) ; 135.6 
(C); 128.6 (2CH); 128.3 (3CH); 78.9 (C); 66.4 (CH2); 50.9 (CH2); 49.6 (CH2); 40.6 (CH2); 30.0 
(CH2); 29.5 (2CH2); 29.4 (2CH2); 29.2 (2CH2);  28.4 (3CH3); 27.1 (CH2); 26.7 (CH2); HRMS: 
m/z calcd for [C26H44N2O4+H]+ 449.3374, measured 449.3369; 
Preparation of acids (4a-f) 
Pd/C (20 mg, 1 mol %) was added to a solution of 3a-f (0.8 mmol) in methanol (20 mL) and the 
obtained suspension was hydrogenated for 4 h with 50 psi H2 at room temperature. The catalyst 
was removed by filtration and the solvent was evaporated to dryness, leaving acids as white 
solids in 77-100% yields, which were used in the next step without further purification. 
2-(2-(tert-butoxycarbonylamino)ethylamino)acetic acid (4a):  174.5 mg (91%); The obtained 
spectra were in accordance with reported procedure.4 
2-(4-(tert-butoxycarbonylamino)butylamino)acetic acid (4b): 191.1 mg (97%); m.p. 173.0-
177.4 oC; IR: 3368, 2979, 2867, 1690, 1636, 1387, 1177 cm-1; 1H NMR (CD3OD, 200 MHz):  = 
3.50 (s, 2H); 3.10-2.88 (m, 4H); 1.79-1.68 (m, 2H); 1.60-1.31 (m, 11H);  13C NMR (CD3OD, 50 
MHz):  = 171.2 (C); 158.5 (C); 79.9 (C); 50.6 (CH2); 48.2 (CH2); 40.5 (CH2); 28.8 (3CH3); 28.0 
(CH2); 24.5 (CH2); HRMS: m/z calcd for [C11H22N2O4+H]+ 247.1652, measured 247.1653; 
2-(6-(tert-butoxycarbonylamino)hexylamino)acetic acid (4c): 220 mg (100%); m.p. 169.7-
173.1 oC;  IR (ATR): 3371, 2978, 2861, 1690, 1617, 1389, 1176 cm-1;  1H NMR (CD3OD, 200 
MHz): 3.47 (s, 2H); 3.05-2.87 (m, 4H); 1.72-1.61 (m, 3H); 1.54-1.30 (m, 14H);  13C NMR 
(D2O, 50 MHz):  = 170.9 (C); 158.5 (C); 79.8 (C); 50.6 (CH2);  (CH2); 41.1 (CH2); 30.7 (CH2); 
28.8 (3CH3); 27.3 (CH2); 27.1 (CH2);  HRMS: m/z calcd for [C13H26N2O4+H]+ 275.1965, 
measured 275.1969; 
2-(8-(tert-butoxycarbonylamino)octylamino)acetic acid (4d): 186.1 mg (77%); m.p. 119.5-
121.7 oC; IR (ATR): 3362, 2978, 2856, 1689,1596, 1386, 1176 cm-1; 1H NMR (CD3OD, 200 
MHz):  3.59 (s, 2H); 3.08-2.99 (m, 4H); 1.80-1.54 (m, 4H); 1.42 (s, 9H); 1.39-1.28 (m, 8H);  
13C NMR (D2O, 50 MHz):  174.2 (C); 161.3 (C); 79.0 (C); 56.8 (CH2); 51.9 (CH2);  50.2 
(CH2); 30.8 (CH2); 30.4 (CH2); 28.5 (CH2); 28.3 (3CH3); 28.2 (CH2); 21.8 (CH2); 17.7 (CH2);  
HRMS: m/z calcd for [C15H30N2O4+H]+ 303.2278, measured 303.2275; 
2-(10-(tert-butoxycarbonylamino)decylamino)acetic acid (4e): 242.0 mg (100%); m.p. 120.3-
123.5 oC; IR (ATR): 3380, 2924, 2854, 1691, 1564, 1370, 1176 cm-1; 1H NMR (D2O, 500 MHz): 
3.59 (s, 2H); 3.01-2.95 (m, 4H); 1.73-1.64 (m, 2H); 1.41-1.31 (m, 23H); 13C NMR (D2O, 125 
MHz): 170.9 (C); 158.7 (C); 79.9 (C); 50.7 (CH2); 42.5 (CH2); 41.1 (CH2); 31.1 (CH2); 30.7 
(CH2); 30.6 (CH2); 30.5 (CH2); 30.3 (CH2); 28.9 (3CH3); 27.9 (CH2); 27.7 (CH2); 27.4 (CH2); 
HRMS: m/z calcd for [C17H34N2O4+H]+ 331.2591, measured 331.2606; 
2-(12-(tert-butoxycarbonylamino)dodecylamino)acetic acid (4f): 275.2 mg (96%); mp 164.5-
167.3 oC ; IR (ATR): 3380, 2920, 2852, 172, 1691, 1382, 1174 cm-1;  1H NMR (CD3OD, 200 
MHz): 3.46 (s, 2H); 3.04-2.93 (m, 4H); 1.74-1.64 (m, 3H); 1.42-1.30 (m, 26H); 13C NMR 
(CD3OD, 50 MHz): 170.7 (C); 168.9 (C); 79.7 (C); 50.6 (CH2); 41.3 (CH2); 30.9 (CH2); 30.7 
(CH2); 30.5 (CH2); 30.2 (CH2); 28.9 (3CH3); 27,8 (CH2); 27.5 (CH2); 27.2 (CH2); HRMS: m/z 
calcd for [C19H38N2O4+H]+ 359.2904, measured 359.2918;  
Preparation of Boc-protected aminoalkyl fulleropyrrolidines (5a-f) 
A suspension of C60 (0.1 mol), acid 5a-f (0.1 mmol) and paraformaldehyde (0.5 mmol) in 
toluene (100 mL) was refluxed for 45 min. The reaction mixture was cooled down and the 
solvent was evaporated to dryness. Column chromatography on SiO2 using toluene gave 
unreacted C60. Further elution with EtOAc/toluene (1/9) and subsequent precipitation, from 
CH2Cl2/CS2 highly concentrated solution with MeOH, gave pure products 5a-f as brown 
powders in 21-36% yields. 
Boc-protected aminoethyl fulleropyrrolidine (5a): 24.5 mg (27%); The obtained spectra were 
in accordance with reported procedure.7 
Boc-protected aminobutyl fulleropyrrolidine (5b): 19.5 mg (21%); UV-VIS (CH2Cl2): λmax 
(nm): 253, 309, 320 and 431 ( /dm3mol-1cm-1 120000, 49000, 56000 and 4600); IR (ATR): 
3440, 2927, 2777, 1708, 1428, 1166, 526; 1H NMR (CDCl3, 500 MHz): 4.88 (bs, 1H); 4.41 
(s, 4H); 3.34-3.25 (m, 2H); 3.11 (t, 2H, J=7); 1.98 (quintet, 2H, J=7) ; 1.85 (quintet, 2H, J= 7); 
1.45  (s, 9H); 13C NMR (CDCl3, 125 MHz):  155.8 (C); 154.8 (Cf(12)); 147.2 (Cf(17)); 146.2 
(Cf(7)); 146.0 (Cf(11));  145.9 (Cf(16)); 145.6 (Cf(5)); 145.3 (Cf(9)); 144.5 (Cf(15)); 143.0 
(Cf(8)); 142.6 (Cf(6)); 142.2 (Cf(14)); 141.9 (Cf(4)); 141.8 (Cf(12,13)); 140.8 (Cf(10)); 136.2 
(Cf(3)); 78.9 (C); 70.5 (2C); 67.8 (2CH2); 54.3 (CH2); 40.5 (CH2); 28.4 (3CH3); 28.0 (CH2); 26.2 
(CH2): HRMS: m/z calcd for [C71H22N2O2+H]+ 935.1754, measured 935.1785 
Boc-protected aminohexyl fulleropyrrolidine (5c): 34.7 mg (36%); UV-VIS (CH2Cl2): λmax 
(nm): 252, 308, 322 and 432 ( /dm3mol-1cm-1 130000, 48000, 55000 and 4400); IR (ATR): 
3442, 2928, 2775, 1688, 1428, 1166, 526. cm-1; 1H NMR (CDCl3, 500 MHz):  4.55 (bs, 1H); 
4.39 (s, 4H); 3.19-3.18 (m, 2H); 3.07 (t, 2H, J=7.5); 1.95 (quintet, 2H); 1.68-1.58 (m, 4H); 1.54-
1.49 (m, 11H); 13C NMR (CDCl3, 125 MHz): 155.7 (C); 154.9 (Cf(12)); 147.2 (Cf(17)); 
146.1 (Cf(7)); 146.0 (Cf(11));  145.9 (Cf(16)); 145.6 (Cf(5)); 145.3 (Cf(9)); 144.5 (Cf(15)); 142.9 
(Cf(8)); 142.5 (Cf(6)); 142.1 (Cf(14)); 141.9 (Cf(4)); 141.8 (Cf(12,13)); 140.1 (Cf(10)); 136.1 
(Cf(3));  78.8 (C); 70.5 (2C); 67.9 (2CH2); 54.9 (CH2); 40.6 (CH2); 30.2 (CH2); 28.8 (CH2); 28.4 
(3CH3);  27.4 (CH2); 26.8 (CH2); HRMS: m/z calcd for [C73H28N2O2+H]+  963.2067, measured 
963.2067; 
 
Boc-protected aminooctyl fulleropyrrolidine (5d): 22.8 mg (23%); UV-VIS (CH2Cl2): λmax 
(nm): 253, 308, 320 and 430 ( /dm3mol-1cm-1 130000, 51000, 54000 and 4800); IR (ATR): 
3446, 2928, 2796,  1703, 1513,  1171, 737 cm-1; 1H NMR (CDCl3, 500 MHz): 4.44 (bs, 1H); 
4.39 (s, 4H); 3.14-3.10 (m, 2H); 3.08-3.05 (m, 2H); 1.96-1.90 (m, 2H); 1.65-1.59 (m, 2H); 1.53-
1.43 (m, 11H); 13C NMR (CDCl3, 125 MHz): 155.5 (C); 154.9 (Cf(12));  147.1 (Cf(17)); 
146.1 (Cf(7)); 146.0 (Cf(11)); 145.5 Cf(16)); 145.3 (Cf(5)); 145.2(Cf(9)); 144.4 (Cf(15)); 143.0 
(Cf(8)); 142.5 (Cf(6)); 142.1 (Cf(14)); 141.9 (Cf(4)); 141.8 (Cf(12,13)); 140.0 (Cf(10)); 136.1 
(Cf(3));  78.9 (C); 70.5 (2C); 67.9 (2CH2); 55.0 (CH2); 40.6 (CH2); 30.21 (CH2); 29.7 (CH2); 
29.4 (CH2); 28.9 (CH2); 28.3 (3CH3); 27.7 (CH2); 26.9 (CH2); HRMS: m/z calcd for 
[C75H32N2O2+H]+ 991.2380, measured  991.2386; 
Boc-protected aminodecyl fulleropyrrolidine (5e): 27.5 mg (27%); UV-VIS (CH2Cl2): λmax 
(nm): 253, 309, 321 and 430 ( /dm3mol-1cm-1 115000, 49000, 54000 and 4900);  IR (ATR); 
3446, 2928, 2855, 1703, 1513, 1171, 737; 1H NMR (CDCl3, 200 MHz): 4.72 (bs, 1H);  
4.41(s, 4H); 3.12-3.04 (m, 2H); 2.02-1.87 (m, 2H); 1.57-1.13 (m, 24H); 13C NMR (CDCl3, 50 
MHz): 155.9 (C); 155.0 (Cf(12)); 147.3 (Cf(17)); 146.2 (Cf(7)); 146.0 (Cf(11)); 145.7 
(Cf(16)); 145.4 (Cf(5)); 145.3 (Cf(9)); 144.6 (Cf(15)); 143.1 (Cf(8)); 142.6 (Cf(6)); 142.3 (Cf(14)); 
142.1 (Cf(4)); 141.9 (Cf(12,13)); 140.1 (Cf(10)); 136.2 (Cf(3));  78.9 (C); 70.5 (2C); 68.0 (2CH2); 
55.3 (CH2); 40.6 (CH2); 30.1 (2CH2); 29.6 (2CH2); 29.3 (CH2); 28.9 (CH2); 28.4 (3CH3, ); 27.7 
(CH2); 26.8 (CH2); MALDI/TOF: m/z measured for [C77H36N2O2+H]+  
Boc-protected aminododecyl fulleropyrrolidine 5f: 24.1 mg (23%); UV-VIS (CH2Cl2): λmax 
(nm): 254, 310, 322 and 432 ( /dm3mol-1cm-1 120000, 48000, 55000 and 4800); IR (ATR): 
3448, 3366, 2927,  1741, 1464, 1174  cm-1; 1H NMR (CDCl3, 500 MHz): 4.39 (s, 4H); 3.09-
3.05 (s, 2H); 1.96-1.90 (m, 2H); 1.64-1.90 (s, 2H); 1.49-1.30 (s, 25H); 13C NMR (CDCl3, 125 
Mhz):  = 155.1 (Cf(12)); 147.3 (Cf(17)); 146.3 (Cf(7)); 146.1 (Cf(11));  146.0 (Cf(16)); 145.7 
(Cf(5)); 145.5 (Cf(9)); 144.6 (Cf(15));  143.1 (Cf(8)); 142.7 (Cf(6)); 142.3 (Cf(14)); 142.1 (Cf(4)); 
141.9 (Cf(12,13)); 140.2 (Cf(10)); 136.3 (Cf(3)); 70.7 (2C); 68.1 (2CH2,); 55.2 (CH2); 40.7 
(CH2); 30.4 (CH2); 29.9 (4CH2); 29.6 (2CH2); 29.1 (CH2); 28.4 (3CH3); 27.9 (CH2); 27.0 (CH2); 
HRMS: m/z calcd for [C79H40N2O2+H]+ 947.2482, measured 947.2482; 
Preparation of fulleropyrrolidine alkyl ammonium salts (6a-f) 
A solution of t-butyl ester 5a-f (0.02 mmol) in 0.45 mL CH2Cl2/TFA mixture (1/2) was stirred at 
room temperature for 2 h and than evaporated to dryness. Excess of TFA was removed by co-
evaporation with toluene leaving amines 6a-f as dark brown powders in almost quantitative 
yields. 
6a: 17.0 mg (94%); The obtained spectra were in accordance with reported procedure.8 
6b: 19.0 mg (100%); UV-VIS (MeOH): λmax (nm): 254, 308, 320 and 431 ( /dm3mol-1cm-1 
130000, 47000, 58000 and 4900); IR (ATR): 2946, 1675, 1200, 798, 722, 525 cm-1; HRMS: m/z 
calcd for [C66H14N2+H]+  835.1230, measured 835.1228; 
6c: 19.5 mg (100%); UV-VIS (MeOH): λmax (nm): 254, 309, 322 and 430 ( /dm3mol-1cm-1 
119000, 47000, 58000 and 4600); IR (ATR): 2915, 1668, 1167, 794, 725, 523 cm-1; HRMS: m/z 
calcd for [C68H18N2+H]+  863.1543, measured 863.1527; 
6d: 15.5 mg (97%); UV-VIS (MeOH): λmax (nm): 252, 306, 321 and 431 ( /dm3mol-1cm-1 
110000, 48000, 54000 and 4900); IR (ATR): 2926, 1666, 1180, 798, 720, 522 cm-1; HRMS: m/z 
calcd for [C70H22N2+H]+  891.1856, measured 891.1851; 
6e: 20.7 mg (100%); UV-VIS (MeOH): λmax (nm): 254, 309, 320 and 432 ( /dm3mol-1cm-1 
120000, 51000, 55000 and 4600); IR (ATR): 2928, 1673, 1137, 796, 721, 523 cm-1; HRMS:  m/z 
calcd for [C72H26N2+H]+  919.2169, measured 919.2129; 
6f: 21.2 mg (100%); UV-VIS (MeOH): λmax (nm): 253, 308, 322 and 432 ( /dm3mol-1cm-1 
125000, 48000, 54000 and 4700); IR (ATR): 2923, 1683, 1181, 557 cm-1 HRMS: m/z calcd for 
[C74H30N2+H]+  947.2482 measured 947.2483; 
Preparation of fulleropyrrolidine phthalimide dyads 1a-f 
A suspension of 6a-f (0.015 mmol) and phthalic anhydride (0.015 mmol eq.) in AcOH/Pyr, 3:2 
mixture (1 mL) was irradiated in microwave reactor for 30 min., with inner temperature 130C 
and applied pulse of 300W. Obtained reaction mixture was evaporated to dryness and the excess 
of acetic acid was removed by co-evaporation with toluene. The crude product was purified by 
column chromatography on SiO2 with EtOAc-toluene (9/1) mixture as an eluent. Subsequent 
precipitation from CH2Cl2/CS2 highly concentrated solution with MeOH gave pure products 1a-f 
as a brown powder in 40-59% yields. 
Compound 1a: 8.3 mg (59%); UV-VIS (CH2Cl2): λmax (nm): 254, 308, 320, 431 and 704 ( 
/dm3mol-1cm-1 120000, 48000, 55000, 4600 and 650); IR(ATR): 3464, 2926, 1711, 1391, 717 
cm-1; 1H NMR (CDCl3, 500 MHz):  = 7.89-7.87 (m, 2H); 7.73-7.71 (m, 2H); 4.48 (s, 4H); 4.27 
(t, 2H, J=6); 3.47 (t, 2H, J=6); 13C NMR (CDCl3, 125 MHz):  = 168.5 (2C); 154.7 (Cf(12)); 
147.2 (Cf(17)); 146.2 (Cf(7)); 146.1 (Cf(11)); 146.0 (Cf(16)); 145.3 (Cf(5)); 145.2 (Cf(9)); 144.5 
(Cf(15)); 143.0 (Cf(8)); 142.5 (Cf(6)); 142.1 (Cf(14)); 142.0 (Cf(4)); 141.8 (Cf(12,13)); 140.0 
(Cf(10)); 136.1 (Cf(3)); 133.9 (2C);  132.3 (2CH); 123.4 (2CH); 70.6 (2C); 67.8 (2CH2); 50.9 
(CH2); 36.6 (CH2); HRMS: m/z calcd for [C72H12N2O2+H]+ 937.0971, measured  937. 0993;  
Compound 1b: 5.8 mg (40%); UV-VIS (CH2Cl2): λmax (nm): 253, 309, 321, 430 and 703 ( 
/dm3mol-1cm-1 130000, 49000, 56000, 4800 and 700); IR (ATR): 3453, 2927, 2854, 1710, 1395, 
710 cm-1; 1H NMR (CDCl3, 200 MHz):  7.88-7.82 (m, 2H); 7.75-7.69 (m, 2H); 4.38 (s, 4H); 
3.88 (t, 2H, J=6); 3.13 (t, 2H, J=6); 2.08-1.94 (m, 4H); 13C NMR (CDCl3, 50 MHz):  163.5 
(2C); 154.8 (Cf(12)); 146.1 (Cf(11));  145.9 (Cf(16)); 145.3 (Cf(5)); 145.1 (Cf(9));  144.4 
(Cf(15)); 143.0 (Cf(8)); 142.5 (Cf(6)); 142.1 (Cf(14)); 141.9 (Cf(4)); 141.7 (Cf(12,13)); 140.0 
(Cf(10)); 136.1 (Cf(3));  133.7 (2C);  132.1 (2CH); 123.0 (2CH); 70.4 (2C);  67.7 (2CH2); 54.1 
(CH2); 37.6 (CH2); 26.6 (CH2); 26.0 (CH2); HRMS:  m/z calcd for [C74H16N2O2+H]+  965.1284, 
measured 965.1285; HRMS:  [M+H]+ calcd 965.1284, measured 965.1285; 
Compound 1c: 7.5 mg (51%); UV-VIS (CH2Cl2): λmax (nm): 253, 308, 320, 430 and 703 ( 
/dm3mol-1cm-1 118000, 47000, 56000, 4900 and 500); IR (ATR): 3442, 2928, 2852, 1688, 1521, 
718 cm-1; 1H NMR (CDCl3, 200 MHz):  7.87-7.81 (m, 2H); 7.76-7.69 (m, 2H);  4.39 (s, 
2H);3.77 (t, 2H, J=7.2); 3.08 (t, 2H, J=7.2); 1.95-1.46 (m, 12H); 13C NMR (CDCl3, 50 MHz):  
= 167.8 (2C); 155.1 (Cf(12)); 147.3 (Cf(17)); 146.2 (Cf(7)); 146.0 (Cf(11));  145.4 (Cf(16)); 145.2 
(Cf(5)); 145.1 (Cf(9));  144.5 (Cf(15)); 143.0 (Cf(8)); 142.5 (Cf(6)); 142.2 (Cf(14)); 142.0 (Cf(4)); 
141.8 (Cf(12,13)); 140.1 (Cf(10)); 136.2 (Cf(3)); 133.8 (2C);  132.1 (2CH; 123.2 (2CH); 70.6 
(2C); 67.9 (2CH2); 54.9 (CH2); 37.9 (CH2); 28.6 (2CH2); 27.2 (CH2); 26.8 (CH2); HRMS: m/z 
calcd for [C76H20N2O2+H]+ 993.1597, measured 993.1593; 
Compound 1d: 6.9 mg (45%); UV-VIS (CH2Cl2): λmax (nm): 254, 310, 322, 432 and 704 ( 
/dm3mol-1cm-1 130000, 50000, 56000, 5100 and 700); IR (ATR): 3457, 2925, 2851, 1711, 1393, 
717; 1H NMR (CDCl3, 200 MHz):  7.86-7.79 (m, 2H); 7.74-7.66 (m, 2H); 4.39 (s, 4H); 3.71 
(t, 2H, J=7.6); 3.06 (t, 2H, J=7.6); 2.03-1.86 (2H); 1.80-1.39 (m, 4H); 13C NMR (CDCl3, 50 
MHz):  = 168.3 (2C); 155.1 (Cf(12)); 147.2 (Cf(17)); 146.2 (Cf(7)); 146.1 (Cf(11));  145.9 
(Cf(16)); 145.6 (Cf(5)); 145.3 (Cf(9)); 145.2 (Cf(15)); 144.5 (Cf(8)); 142.5 (Cf(6)); 142.2 (Cf(14)); 
142.0 (Cf(4)); 141.8 (Cf(12,13)); 140.1 (Cf(10)); 136.2 (Cf(3)); 133.8 (2C); 132.2 (2CH); 123.1 
(2CH); 70.6 (2C); 67.9 (2CH2); 55.1 (CH2); 37.9 (CH2); 29.5 (2CH2); 29.2 (2CH2); 28.8 (CH2); 
28.6 (CH2); 27.6 (CH2); 26.8 (CH2); HRMS: m/z calcd for [C78H24N2O2+H]+ 1021.1910, 
measured 1021.1912;  
Compound 1e: 9.1 mg (58%); UV-VIS (CH2Cl2): λmax (nm): 252, 308, 322, 432 and 704 ( 
/dm3mol-1cm-1 125000, 47000, 54000, 4800 and 600); IR (ATR): 3464, 2926, 2851, 1711, 1394, 
718; 1H NMR (CDCl3, 200 MHz):  7.86-7.75 (m, 2H); 7.72-7.68 (m, 2H); 4.40 (s, 4H); 3.69 
(t, 2H, J=7.5); 3.07 (t, 2H, J=7.5); 2.01-1.86 (m, 2H); 1.72-1.24 (m, 14H); 13C NMR (CDCl3, 50 
MHz):  = 168.3 (2C); 155.1 (Cf(12)); 147.2 (Cf(17)); 146.2 (Cf(7)); 146.1 (Cf(11)); 146.0 
(Cf(16)); 145.4 (Cf(5)); 145.3 (Cf(9)); 145.2 (Cf(15)); 144.5 (Cf(8)); 142.5 (Cf(6)); 142.2 (Cf(14)); 
142.0 (Cf(4)); 141.8 (Cf(12,13)); 140.1 (Cf(10)); 136.2 (Cf(3));  133.8 (2C);  132.2 (2CH); 123.1 
(2CH); 70.6 (2C);  67.9 (2CH2); 55.1 (CH2); 38.0 (CH2); 29.6 (CH2); 29.5 (CH2) 29.2 (2CH2);  
28.9 (CH2); 28.6 (CH2); 27.0 (CH2); 26.9 (CH2); HRMS: m/z calcd for [C80H28N2O2+H]+ 
1049.2223, measured 1049.2234; 
Compound 1f: 9.2 mg (57%); UV-VIS (CH2Cl2): λmax (nm): 253, 309, 320, 431 and 703 ( 
/dm3mol-1cm-1 118000, 49000, 54000, 4800 and 540); IR(ATR): 3662, 2926, 2855, 1688, 1386, 
720; 1H NMR (CDCl3, 500 MHz):  = 7.85-7.83 (m, 2H); 7.71-7.69 (m, 2H); 4.41 (s, 4H); 3.68 
(t, 2H, J=7.4); 3.08 (t, 2H, J=7.4); 1.98-1.92 (2H); 1.69-1.59 (m, 4H); 1.51-1.45 (2H); 1.45-1.32 
(12H); 13C NMR (CDCl3, 125 MHz):  = 168.5 (2C); 155.2 (Cf(12)); 147.3 (Cf(17));  146.2 
(Cf(7)); 146.1 (Cf(11));  146.0 (Cf(16)); 145.7 (Cf(5)); 145.4 (Cf(9)); 145.3 (Cf(15)); 144.6 
(Cf(8)); 142.6 (Cf(6)); 142.3 (Cf(14)); 142.1 (Cf(4)); 141.9 (Cf(12,13)); 140.1 (Cf(10)); 136.2 
(Cf(3));  133.8 (2C); 132.2 (2CH); 123.1 (2CH); 70.7 (2C);  68.0 (2CH2); 55.2 (CH2); 38.1 
(CH2); 29.6 (3CH2); 29.5 (CH2); 29.2 (2CH2); 28.8 (CH2); 28.6 (CH2); 27.7 (CH2); 26.9 (CH2); 
HRMS: m/z calcd for [C82H32N2O2+H]+  1077.2536, measured 1077.2550; 
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